Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12101122 | 0.83 | SMN1; SMN2 (0.41) | PTPN11SMN1; SMN2RAB9AKDM4EMEN1 | |
| SCHEMBL21138401 | 0.82 | MAPT (0.56) | PTPN11SMN1; SMN2RAB9AKDM4EMEN1 | |
| SCHEMBL23880572 | 0.80 | MEN1 (0.50) | PTPN11RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL13379288 | 0.79 | PTPN11 (0.61) | PTPN11 | |
| SCHEMBL17792928 | 0.79 | RXFP1 (0.57) | PTPN11SMN1; SMN2RAB9AKDM4EMEN1 | |
| SCHEMBL1239633 | 0.78 | MAPT (0.51) | PTPN11RAB9AKDM4EMEN1ALDH1A1 | |
| SCHEMBL3309759 | 0.78 | PTPN11 (0.59) | PTPN11 | |
| SCHEMBL626576 | 0.77 | MAPT (0.57) | SMN1; SMN2RAB9AKDM4EMEN1ALDH1A1 | |
| SCHEMBL474661 | 0.77 | KMT2A (0.70) | SMN1; SMN2RAB9AKDM4EMEN1ALDH1A1 | |
| SCHEMBL3307191 | 0.77 | NPC1 (0.60) | SMN1; SMN2RAB9AKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115297860-B | Novel N-aryl oxamic acids | 普渡研究基金会 | 2024-10-15 | — | — | CN | disclosed |
| EP-4132523-A1 | NOVEL N-ARYL OXAMIC ACIDS | Purdue Research Foundation (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115297860-A | Novel N-aryl-oxalamic acids | 普渡研究基金会 | 2022-11-04 | — | — | CN | disclosed |
| US-11192850-B2 | N-aryl oxamic acids | PURDUE RESEARCH FOUNDATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210309606-A1 | Novel N-aryl Oxamic Acids | PURDUE RESEARCH FOUNDATION (US) | 2021-10-07 | — | — | US | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309606-A1 | Novel N-aryl Oxamic Acids | PTPRB, PTPRO, PTPRM | PTPN11 23/4885SMN1; SMN2 3872/4885RAB9A 2293/4885 |
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | PTPN11 4497/4885SMN1; SMN2 763/4885RAB9A 3871/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | PTPN11 4737/4885SMN1; SMN2 1044/4885RAB9A 3368/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | PTPN11 4663/4885SMN1; SMN2 473/4885RAB9A 3294/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | PTPN11 4663/4885SMN1; SMN2 473/4885RAB9A 3294/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | PTPN11 4663/4885SMN1; SMN2 473/4885RAB9A 3294/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | PTPN11 4650/4885SMN1; SMN2 656/4885RAB9A 3496/4885 |
| US-11192850-B2 | N-aryl oxamic acids | PTPRB, PTPRO, PTPRM | PTPN11 23/4885SMN1; SMN2 3605/4885RAB9A 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.